Molecule
Ubrogepant is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Ubrogepant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.
Source: US FDA prescribing information
Ubrogepant is a calcitonin gene-related peptide receptor antagonist.
Source: US FDA prescribing information
The recommended dose is 50 mg or 100 mg taken orally, as needed. If needed, a second dose may be administered at least 2 hours after the initial dose. The maximum dose in a 24-hour period is 200 mg. Severe Hepatic or Severe Renal Impairment: Recommended dose is 50 mg, if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
Source: US FDA prescribing information
UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. Reactions have included anaphylaxis, dyspnea, and facial or throat edema Concomitant use with strong CYP3A4 inhibitors. History of serious hypersensitivity to ubrogepant or any component of UBRELVY.
Source: US FDA prescribing information
Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue UBRELVY and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis and dyspnea. These reactions can occur within minutes, hours, or days after administration. Hypertension: New-onset or worsening of pre-existing hypertension may occur. Raynaud’s phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur. 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported with use of UBRELVY. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions occurred within hours after dosing and were not serious, and some reactions led to discontinuation.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in labeling: Hypersensitivity Reactions Hypertension Raynaud’s Phenomenon The most common adverse reactions (at least 2% and greater than placebo) were nausea and somnolence.
Source: US FDA prescribing information
Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. For additional dose modifications for moderate or weak CYP3A4 inhibitors and inducers or BCRP and/or P-gp only inhibitors, refer to section 2.2.
Source: US FDA prescribing information
Store between 20°C and 25°C (68°F and 77°F): excursions permitted between 15°C and 30°C (59°F and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Ubrogepant, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ubrelvy 100 mg tabletOral | Allergan | US FDA | Available on request |
| Ubrelvy 50 mg tabletOral | Allergan | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 23 December 2019 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 2 presentations of Ubrogepant and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ubrogepant, including Ubrelvy.
Yes. The US FDA first approved Ubrogepant on 23 December 2019, according to Drugs@FDA.
No listed presentation of Ubrogepant is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.